Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:8/27/2008

SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will participate in three upcoming conferences in September during which he will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

-- The Thomas Weisel Partners Healthcare Conference on Wednesday, September 3, at 4:25 p.m. Eastern Time at the Four Seasons Hotel in Boston

-- BioCentury's NewsMakers in the Biotech Industry Conference on Thursday, September 4, at 2:30 p.m. Eastern Time at the Millennium Broadway Hotel in New York

-- The 3rd Annual Citi Biotech Day on Monday, September 8, at 2:35 p.m. Eastern Time at the Citi Center in New York

Live audio webcasts of Poniard's presentations at the Thomas Weisel Partners Healthcare Conference and Citi Biotech Day will be available for 10 business days following each conference. Each webcast can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors,
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... and NYSE: SNY) today announced that the Companies intend ... rare pediatric disease priority review voucher in connection with ... priority review voucher entitles the holder to designate a ... 6-month review from the filing date instead of the ...
(Date:7/30/2014)... , July 30, 2014  The Chicago Bears are ... Academy of Dermatology (Academy) in an effort to raise ... Bears will host free SPOT me™ skin cancer screenings ... at Soldier Field. SPOT me™ is an educational ... the dangers and risks of skin cancer, and encourages ...
(Date:7/30/2014)... July 30, 2014 Sales Horizons, a ... of blended sales training programs for companies engaged in ... programs used by thousands of salespeople over 25 years ... training program can be customized to address the unique ... blended sales training program consists of two ...
(Date:7/30/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... in Industrial Applications , the global market for industrial ... by 2018, registering a five-year compound annual growth rate ... recorded in the detergent enzyme segment with a CAGR ... has influenced almost every sector of industrial activity, ranging ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3
... (NYSE: SGP ) announced that Nippon Organon ... Drug Application with the Japanese,Ministry of Health, Labour ... selective relaxant binding agent (SRBA), sugammadex., Sugammadex ... the effects of certain muscle relaxants, rocuronium bromide,(marketed ...
... The Science and Technology Foundation of,Japan announced the ... Japan,Prize today., All three laureates this year ... and Dr. Robert Elliot Kahn who received their ... for the,Internet" in the prize category of "Information ...
... Both Clinical Trial Experience and Business ... CAMBRIDGE, Mass., Jan. 16 Cytel, Inc. ... Irving Dark has,accepted the role of Vice President ... Cytel 15-years of management experience guiding drug,biologic and ...
Cached Biology Technology:Schering-Plough Announces Sugammadex New Drug Application Filed in Japan 2Schering-Plough Announces Sugammadex New Drug Application Filed in Japan 3American Scientists Named as Laureates of the 2008 (24th) Japan Prize 2Irving Dark Named Vice President of Cytel Clinical Research Services 2
(Date:7/30/2014)... in female baboons suggests that the route to a higher ... have lots of supportive sisters. , A female baboon,s social ... the rank of her mother - the higher the mother ... reason, dominance rank in female baboons is thought to be ... a good spot in the pecking order, whereas females born ...
(Date:7/30/2014)... could be as simple as inserting a medicated, disappearing ... Washington bioengineers have discovered a potentially faster way to ... HIV. Their method spins the drug into silk-like fibers ... higher doses of the drug than possible with other ... could offer women a potentially more effective, discreet way ...
(Date:7/30/2014)... ranges and a changing climate threaten some of ... and so conservationists establish seed collections to save ... hopes of preserving some genetic diversity., For decades, ... models that offer a one-size-fits-all approach for how ... 50 seed samples regardless of species, pollination mode, ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3Saving seeds the right way can save the world's plants 2
... global carbon cycle, helping sequester significant amounts of carbon. ... that they discolor coastal waters and reduce the amount ... known as "red tide," the term "harmful algal blooms" ... of algal biomass can sometimes also turn the ocean ...
... of scientists studying genetic pathways that are mutated in ... forms of congenital heart disease including hypertrophic cardiomyopathy ... the leading cause of sudden death in children and ... and successfully treated HCM in the lab. ...
... Massachusetts Institute of Technology biologist Graham Walker leads a ... recreate the creativity and excitement of his research lab: ... MIT colleagues to identify new research questions in science ... Walker will talk about his experiences running a science ...
Cached Biology News:Brown tide culprit sequenced: Genome of the first of algal bloom species 2Brown tide culprit sequenced: Genome of the first of algal bloom species 3Brown tide culprit sequenced: Genome of the first of algal bloom species 4Cancer-related pathways reveal potential treatment target for congenital heart disease 2Cancer-related pathways reveal potential treatment target for congenital heart disease 3Plenary speech by HHMI professor highlights efforts of scientist-educators 2Plenary speech by HHMI professor highlights efforts of scientist-educators 3
... Translation System is ideal for both radioactive ... Translation System: Provides five pre-mixed nucleotide ... Yields >10 8 cpm/g control ... to monitor the performance of the system ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
... Direct SPA Screening Assay, 5 ... that eliminate lengthy sample extraction procedures ... use).Range: 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: 0.65 ... 2-8 C. Category: Drug Screening & ...
Biology Products: